Randomized controlled trials of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists, which have diuretic and BP lowering effects, have shown promising results in reducing cardiovascular mortality and/or heart failure hospitalizations in cohorts with T2D or heart failure [49–52]. The gene discussed is GLP1R; the disease is heart failure.